Pink SheetThe US Food and Drug Administration’s July advisory committee schedule includes a curious mix of vaccine safety reviews and the potentially triumphant return of a pulled multiple myeloma drug, in addi
ScripBiopharmaceutical companies raised just $13.1bn during the first quarter of 2025 – less than half of the $30.1bn raised in Q1 of 2024, the latest Financing Quarterly Statistics report from Biomedtra
Pink SheetThe regenerative medicine sector continues to seek increased contact with the US Food and Drug Administration, even as the architects of the Center for Biologics Evaluation and Research review structu
ScripAtsena Therapeutics thinks it can be a success story in the gene therapy field, where some companies have recently stumbled, with the closure of a funding round that it plans to use especially for its